In humans, a CML LSC is operationally defined as a leukemia cell resistant to ABL TKIs after being transferred to immune-deficient mice and passing one or more in vitro or in vivo assays [5]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.